Press Release
News
Media Coverage
News

Ascentage Pharma to Present at the 36th Annual J.P. Morgan Healthcare Conference

Date | 2018.01.05

ROCKVILLE, MD and HONG KONG, CHINA,Jan. 5, 2018/PRNewswire/-- Ascentage Pharma, a global clinical-stage biopharmaceutical company dedicated to developing apoptosis-targeted therapies for cancers and other diseases, today announced that Dajun Yang, M.D., Ph.D., the Company’s Chairman & Chief Executive Officer, will present a corporate overview at the 36th Annual J.P. Morgan Healthcare Conference on Wednesday, January 10, 2018 at 8:00 a.m. PST at the Westin St. Francis Hotel in San Francisco, California, USA.

 

About Ascentage Pharma

Pharma is a globally-focused, clinical-stage biopharmaceutical company developing novel small molecule therapies for cancers, hepatitis B and aging-related diseases. Based on breakthrough technology from the University of Michigan, the Company’s expertise is in designing therapeutics that inhibit protein-protein interactions to restore apoptosis, or programmed cell death, in cancers. Ascentage has built a rich pipeline of six clinical candidates, including a novel, highly potent Bcl-2/Bcl-xL inhibitor, APG-1252, as well as candidates aimed at IAP and MDM2-p53 pathways, and next-generation tyrosine kinase inhibitors. For more information, please visit www.ascentagepharma.com.

 

Media Contact

Amy Bonanno

E-mail: abonanno@bmccommunications.com

Phone: +1 914 450 0349


Investor Contact

Chad Rubin

E-mail: crubin@troutgroup.com

Phone: +1 646 378 2947